Ovid Therapeutics Inc.

Historical 13F Holders

Symbol
OVID
CUSIP
690469101
All holders as of
Q3 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 690469101 since 12/18/2024, largest first.

Filer % of Class Filed
Takeda Pharmaceutical Co Ltd 13G/A
12.3% 12/9/2025
Event 12/8/2025
Janus Henderson Group PLC 13G 10.0% 12/8/2025
Event 11/28/2025
Sirenia Capital Management LP 13G
9.9% 5/15/2026
Event 3/31/2026
Affinity Asset Advisors, LLC 13G/A
7.9% 8/13/2026
Event 6/30/2026
RA Capital Management, L.P. 13G/A
7.8% 11/16/2026
Event 9/30/2026
Eventide Asset Management, LLC 13G/A
6.3% 8/14/2026
Event 6/30/2026
BlackRock, Inc. 13G 5.8% 7/29/2026
Event 6/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (8)
Balyasny Asset Management L.P. 13G/A
4.99% 8/14/2026
Event 6/30/2026
Jeremy M. Levin 13G/A 4.5% 5/14/2026
Event 3/31/2026
Federated Hermes, Inc. 13G/A
4.2% 7/8/2026
Event 6/30/2026
Madison Avenue Partners, LP 13G/A
4.0% 2/14/2025
Event 12/31/2024
ADAR1 Capital Management, LLC 13G/A
3.5% 11/16/2026
Event 9/30/2026
Point72 Asset Management, L.P. 13G/A
1.3% 5/15/2026
Event 3/31/2026
Rubric Capital Management LP 13G/A
0.7% 7/9/2025
Event 6/30/2025
Biotechnology Value Fund L P 13G/A
0% 7/21/2025
Event 7/17/2025

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 130 148 M $369M
2026 Q2 131 147 M $396M
2026 Q1 103 105 M $233M
2025 Q4 84 61.8 M $101M
2025 Q3 81 36.2 M $47.1M
2025 Q2 73 36.0 M $11.9M
2025 Q1 83 46.4 M $14.5M
2024 Q4 83 47.6 M $44.4M
2024 Q3 77 46.3 M $54.6M
2024 Q2 77 46.0 M $35.4M
2024 Q1 82 50.1 M $153M
2023 Q4 78 51.7 M $166M
2023 Q3 65 42.3 M $163M
2023 Q2 70 41.0 M $135M
2023 Q1 62 38.7 M $99.8M
2022 Q4 61 38.6 M $71.7M
2022 Q3 61 35.6 M $65.5M
2022 Q2 58 34.6 M $74.5M
2022 Q1 63 35.1 M $110M
2021 Q4 68 34.0 M $109M
2021 Q3 73 33.6 M $113M
2021 Q2 83 33.4 M $131M
2021 Q1 91 36.3 M $146M
2020 Q4 86 27.6 M $64.5M
2020 Q3 95 25.1 M $144M
2020 Q2 82 21.8 M $161M
2020 Q1 60 15.9 M $47.3M
2019 Q4 64 17.8 M $73.7M
2019 Q3 40 8.21 M $26.6M
2019 Q2 37 10.1 M $18.7M
2019 Q1 51 12.3 M $21.7M
2018 Q4 48 6.84 M $16.5M
2018 Q3 50 7.64 M $43.3M
2018 Q2 48 7.95 M $62.0M
2018 Q1 48 7.05 M $49.8M
2017 Q4 49 7.82 M $77.2M
2017 Q3 42 7.22 M $61.5M
2017 Q2 46 7.99 M $81.8M